Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

South Korea's Celltrion to merge with affiliates to set up holding company structure

09/25/2020 | 03:48am EST
The logo of Celltrion is seen at company's headquarters in Incheon

South Korean pharmaceutical company Celltrion said in a regulatory filing on Friday that it plans to merge with affiliates Celltrion HealthCare, Celltrion Pharm to establish a holding company structure by end-2021.

Celltrion, whose experimental COVID-19 treatment has been approved by South Korea for Phase 2/3 clinical trials, said the merger will take place when requirements for South Korean fair trade rules are met.

(Reporting by Joyce Lee. Editing by Jane Merriman)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION HEALTHCARE CO LTD End-of-day quote.
CELLTRION PHARM INC End-of-day quote.
CELLTRION, INC. -0.15% 329500 End-of-day quote.82.04%
All news about CELLTRION, INC.
11/26CELLTRION : Phase II trial to study anti-COVID-19 mAb CT-P59 completes enrolment
AQ
11/06CELLTRION, INC. : quaterly earnings release
11/05Celltrion's COVID-19 antibody drug cut recovery time-early study
RE
11/05CELLTRION HEALTHCARE : says Phase 1 trial shows COVID-19 antibody drug 'well-tol..
RE
11/04S.Korea shares extend gains as investors eye tight U.S. election race
RE
11/03S.Korea stocks gain most in nearly 5 months on strong global data
RE
10/27S.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate
RE
10/26S.Korea shares dip as surging global coronavirus cases dent sentiment
RE
10/26South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisati..
RE
10/25S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation
RE
More news
Financials
Sales 2020 1 871 B 1,69 B 1,69 B
Net income 2020 583 B 0,53 B 0,53 B
Net cash 2020 498 B 0,45 B 0,45 B
P/E ratio 2020 76,9x
Yield 2020 0,00%
Capitalization 44 665 B 40 355 M 40 422 M
EV / Sales 2020 23 866x
EV / Sales 2021 20 726x
Nbr of Employees 908
Free-Float 68,3%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 313 555,56 KRW
Last Close Price 334 000,00 KRW
Spread / Highest target 34,7%
Spread / Average Target -6,12%
Spread / Lowest Target -63,5%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.82.04%39 811
LONZA GROUP AG55.15%44 901
MODERNA, INC.458.18%43 204
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832
IMMUNOMEDICS, INC.315.22%20 324